NetworkNewsBreaks – CytoDyn Inc. (CYDY) Reports Improved Response Rate to Increased Dosage in HIV Phase 3 Monotherapy Trial
Biotechnology company CytoDyn (OTCQB: CYDY) this morning announced that it has received clearance from the independent Institutional Review Board (“IRB”) overseeing its CD03 phase 3 investigative monotherapy trial to increase the weekly PRO 140 dose from 525 mg to 700 mg for newly enrolled patients. The trial’s objective is to evaluate the efficacy, safety and tolerability of PRO 140 as a long-acting, single-agent maintenance therapy for the chronic suppression of HIV. Current participants in the trial that were not able to maintain suppressed HIV viral load on a lower dose of PRO 140 will be allowed to continue in the…







